ZELNORM
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jul 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZELNORM (tegaserod) is an oral small-molecule 5-HT4 receptor agonist approved in 2002 for gastrointestinal motility disorders. It stimulates peristaltic reflex, enhances intestinal secretion, and normalizes impaired motility throughout the GI tract. The drug also inhibits visceral sensitivity and enhances basal motor activity.
LOE Approaching
Product is in late-stage maturity with LOE approaching; commercial teams should anticipate resource reallocation and transition planning within the next 1–3 years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZELNORM currently has zero linked job openings, reflecting its mature, declining commercial stage. Career opportunities on this product are limited and likely focused on transition planning, generic erosion mitigation, and managed care negotiations rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on ZELNORM at Alfasigma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.